用间充质干细胞治疗改善肾血管性疾病患者的肾功能。
Improving human kidney function in renovascular disease with mesenchymal stem cell therapy.
机构信息
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA; School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia; Central Northern Adelaide Renal Transplantation Service, Royal Adelaide Hospital, South Australia, Australia.
出版信息
Kidney Int. 2020 Apr;97(4):655-656. doi: 10.1016/j.kint.2019.12.020.
A dose escalation study of adipose-derived human mesenchymal stem cell (MSC) therapy was studied in 21 subjects. This dose escalation study confirmed no significant cellular toxicity, but it showed improvement in renal oxygenation and glomerular filtration rate. No significant renal toxicity from cell therapy was shown. A reduction in inflammatory markers including tumor necrosis factor-α, interferon-γ, and neutrophil gelatinase-associated lipocalin was noted in subjects receiving MSC therapy. This study provides short-term safety and renal efficacy for MSC therapy and paves the way forward for future MSC-based interventions in renovascular disease.
一项脂肪来源的人骨髓间充质干细胞（MSC）治疗的剂量递增研究在 21 名受试者中进行。这项剂量递增研究证实没有明显的细胞毒性，但它显示出改善肾脏氧合和肾小球滤过率。细胞治疗没有显示出明显的肾毒性。接受 MSC 治疗的受试者的炎症标志物包括肿瘤坏死因子-α、干扰素-γ 和中性粒细胞明胶酶相关脂质运载蛋白的水平降低。这项研究为 MSC 治疗提供了短期的安全性和肾脏疗效，并为未来基于 MSC 的肾血管疾病干预铺平了道路。
Zotero 插件